Somewhat Positive Media Coverage Somewhat Unlikely to Affect Eli Lilly and (LLY) Share Price
Press coverage about Eli Lilly and (NYSE:LLY) has trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eli Lilly and earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.1228901005862 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Eli Lilly and Company: Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis (twst.com)
- Eli Lilly’s (LLY) Upgraded to Buy (investorplace.com)
- Understanding Eli Lilly’s Valuation This November (finance.yahoo.com)
- Understanding Eli Lilly’s Estimates after 3Q17 (finance.yahoo.com)
- Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis (finance.yahoo.com)
LLY has been the topic of several recent analyst reports. BMO Capital Markets reissued a “sell” rating and set a $73.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. BidaskClub downgraded shares of Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Jefferies Group reissued a “buy” rating and set a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Finally, Leerink Swann reaffirmed a “hold” rating on shares of Eli Lilly and in a research note on Thursday, August 31st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $90.25.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. research analysts anticipate that Eli Lilly and will post 4.21 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.44%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is currently 98.58%.
In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold 592,003 shares of company stock valued at $50,246,641 in the last three months. Company insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.